{"slug":"tcr-t","tag":"tcr-t","variants":["tcr-t"],"description":"No description yet","count":2,"kinds":{"person":1,"company":1},"related":[{"slug":"cell-therapy","tag":"cell-therapy","shared":1},{"slug":"owner-request","tag":"owner-request","shared":1},{"slug":"sarcoma","tag":"sarcoma","shared":1}],"records":[{"id":"sandra-dangelo","kind":"person","name":"Sandra P. D'Angelo","route":"/people/sandra-dangelo/","tldr":"Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour."},{"id":"anocca","kind":"company","name":"Anocca","route":"/companies/anocca/","tldr":"Anocca is a Swedish cell-therapy company building T-cell receptor therapies (TCR-T) that recognise targets from inside cancer cells, with a lab platform that replicates T-cell biology and software to pick the targets."}]}